Therapeutic potential when combining with other drugs used to treat gliomas (Lucena-Cacace et al., 2019; Lucena-Cacace et al., 2017) has been suggested, whilst we additionally and concordantly identify EGFR amplification as a biomarker (Figure 4F). Here, EGFR is linked to central nervous system cancer.